CHICAGO — The 24-month results of the PRO-CON study did not demonstrate a benefit of intravitreal aflibercept injection as prophylaxis against the conversion to neovascular age-related macular degeneration in high-risk eyes, according to a speaker here.
“Quarterly aflibercept prophylaxis did not affect conversion through month 24 in the PRO-CON trial,” Jeffrey S. Heier, MD, said at the American Society of Retina Specialists meeting.
The PRO-CON trial enrolled 128 eyes with high risk, intermediate AMD to evaluate intravitreal anti-VEGF therapy and its potentially prophylactic
Uncategorized